# Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

> **NCT00391846** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 252 (actual)

## Conditions studied

- Heart Failure
- Ventricular Dysfunction, Left

## Interventions

- **DRUG:** Captopril
- **DRUG:** Enalapril
- **DRUG:** Lisinopril
- **DRUG:** Ramipril
- **DRUG:** Trandolapril
- **DRUG:** Bisoprolol
- **DRUG:** Carvedilol
- **DRUG:** Metoprolol succinate
- **DRUG:** Candesartan
- **DRUG:** Valsartan
- **DRUG:** Eplerenone
- **DRUG:** Spironolactone
- **DRUG:** Diuretics
- **DRUG:** HF treatment according to Swedish guidelines
- **PROCEDURE:** Blood samples
- **PROCEDURE:** The Kansas City Cardiomyopathy Questionnaire (KCCQ)

## Key facts

- **NCT ID:** NCT00391846
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2012-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391846, "Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00391846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*